Following corneal graft, local steroids with a gradually decreasing dose for 12 months are prescribed to reduce the graft rejection risk (maximum incidence of 20% for the first 12 months). The validated KaliJAR® device is a box for single-dose eye drops collection. This innovative tool will make it possible to objectify the compliance of patients with a corneal graft.

Unlike the field of glaucoma, no specific compliance data are available for corneal grafts, although it is important because graft rejection is the most important cause of corneal graft failure.

Inclusion Criteria:

• Newly transplanted corneal patients
• Patients able to instill correctly topical corticosteroid treatment
• Patients able to come to control visits
• Patient affiliated or entitled to a social security system
• Patient informed about the study and having signed a consent

Exclusion Criteria:

• Patients under guardianship
• Patients unable to give their consent or to correctly use the collection box

Newly transplanted corneal patients and adult